Navigation Links
Landmark study of more than 27,000 women shows favorable results of Roche's CINtec PLUS cytology test
Date:11/4/2013

TUCSON, Ariz., Nov. 4, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.1 The pan-European study, including more than 27,000 women from five European countries,  was performed to estimate the diagnostic performance of the CINtec® PLUS* cytology test in screening for cervical precancers compared to more traditional screening methods like Pap cytology. The study assessed whether the test, which uses two biomarkers, p16 and Ki-67, that are indicative of oncogenic (cancer-causing) human papillomavirus (HPV) infections, provides both high sensitivity and specificity for high-grade precancerous cervical lesions. The results showed that when compared to Pap cytology testing, the CINtec PLUS cytology test was more effective than Pap cytology in detecting precancerous lesions.  Pap cytology had a sensitivity of 67.5% while the CINtec PLUS test had a sensitivity of 86.7%.

(Photo: http://photos.prnewswire.com/prnh/20131104/LA09354 )

"The results of PALMS confirms data from previous studies which have shown that incorporating the CINtec PLUS test in cervical cancer screening programs can provide real benefit to both clinicians and their patients," says Dr. Christine Bergeron, Laboratoire Cerba, Cergy, Paris, France, PALMS study investigator and publication co-author.  "In young women, where HPV infection rates may be high, the CINtec PLUS test could be very useful to identify those women with clinically significant precancers who may be missed by the lower sensitivity Pap test.  In older women, combining the CINtec PLUS test with HPV DNA testing would make a lot of sense."

More than 500,000 new cases of cervical cancer are diagnosed each year worldwide.2 Disappointingly, the average five-year survival rate of patients is only around 50%.2 HPV infections are common and cause virtually all cervical cancer.2  However, only those women with persistent HPV infections and who have developed high-grade precancerous cervical disease should be treated. The CINtec PLUS cytology test was developed to help identify those HPV infections that may lead to cancer and distinguish them from those that will not.

The authors (Safaeian and Sherman) of an editorial published along with the PALMS study results write that dual biomarker screening could have a role in primary screening, especially in younger women. They also conclude that the dual assay could serve as a triage for positive HPV tests and could dramatically decrease patient referrals to colposcopy and other invasive and costly procedures unnecessarily.

"The results demonstrated in the PALMS trial reinforces the medical value Roche brings to cervical cancer screening.  We are committed to improving patient outcomes by providing differentiated diagnostic tools for doctors and laboratories," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.  "We are pleased to announce that a fully automated version of the CINtec® PLUS cytology test will be launching later this year and will join the cobas® HPV test and the CINtec® Histology test to complete our portfolio of cervical cancer screening products."

*The CINtec® PLUS cytology test is not available in all geographies and/or may not be approved for all uses discussed in this press release.

1JNCI – The Journal of the National Cancer Institute (Ikenberg et al. Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. J Natl Cancer Inst. 2013;105(20):1550-1557); PUBMED: www.ncbi.nlm.nih.gov/pubmed/24096620.

2 World Health Organization Fact Sheet 380, September 2013: http://www.who.int/mediacentre/factsheets/fs380/en/

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. VENTANA, the VENTANA logo and cobas are trademarks of Roche. Other trademarks are the property of their respective owners.

Visit www.ventana.com to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Survey of Participants from Landmark GRACE Trial Provides Patients Perspectives from an HIV Clinical Study
2. Behind the Landmark Weeks Case
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
5. SurgiCount Medical Achieves Landmark Product Usage And Customer Milestones
6. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
7. President Obama Signs Landmark Accessible Prescription Drug Label Bill
8. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
9. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):